ROCKVILLE, Md. — The American Society of Human Genetics (ASHG), the world’s preeminent professional organization for human genetics and genomics, has officially announced the results of its 2027 leadership elections. In a move signaling a strong strategic pivot toward precision medicine, health equity, and the integration of artificial intelligence (AI) in clinical settings, the Society has elected Dr. Wendy Chung as its 2027 President-Elect.
The announcement, released on September 9, 2026, also introduced four new members to the Board of Directors, each bringing a distinct expertise ranging from computational genomics to genetic counseling and public health policy. These appointments arrive at a pivotal moment in the history of genetics, as the field transitions from foundational discovery to the widespread, equitable application of genomic data in healthcare.
The New Vanguard: Meet the 2027 Leadership
The election of Dr. Wendy Chung represents a landmark appointment for the Society. Currently serving as the Chief of Pediatrics at Boston Children’s Hospital and the Mary Ellen Avery Professor of Pediatrics at Harvard Medical School, Dr. Chung is widely regarded as a titan in the field of clinical genetics.
Wendy Chung: A Visionary for Genomic Integration
Dr. Chung’s career has been defined by her ability to bridge the gap between laboratory discovery and patient-centered care. Her work has been instrumental in identifying the genetic basis of more than 60 novel Mendelian conditions, effectively ending diagnostic odysseys for countless families.
Her leadership philosophy emphasizes that genomics must be actionable. By spearheading major studies in newborn screening, autism, and congenital anomalies, she has consistently pushed for the translation of genomic insights into precise risk assessments and personalized treatment plans. Her long history of service to ASHG—including roles on the Board of Directors, as Treasurer, and as a contributor to the American Journal of Human Genetics—positions her to lead the Society with an intimate understanding of its organizational mission and future needs.
A Diverse Board for a Complex Field
The newly elected members of the Board of Directors—Dr. Colleen A. Campbell, Dr. Andrew R. Marderstein, Dr. Athena Starlard-Davenport, and Dr. Brooke N. Wolford—each bring a specific lens to the Society’s strategic vision.
- Dr. Colleen A. Campbell: As a leader at the University of Iowa Health Care, Dr. Campbell offers a critical perspective on the intersection of genetics, policy, and patient advocacy. Her focus on the responsible integration of AI in health care and her commitment to expanding genetic services to rural populations will be vital as ASHG addresses the "urban-rural divide" in genetic access.
- Dr. Andrew R. Marderstein: Representing the next generation of clinical researchers, Dr. Marderstein brings deep expertise in computational genomics and machine learning from Memorial Sloan Kettering Cancer Center. His work on the mechanisms connecting genetic variation to cancer susceptibility is poised to guide ASHG toward more data-driven, predictive health models.
- Dr. Athena Starlard-Davenport: A champion of equity, Dr. Starlard-Davenport’s work at the University of Tennessee Health Science Center on sickle cell disease and breast cancer disparities addresses the moral imperative of the field. Her experience on the Diversity and Inclusion Task Force ensures that ASHG’s future initiatives remain rooted in social justice and equitable health outcomes.
- Dr. Brooke N. Wolford: Based in Norway, Dr. Wolford’s work with Nordic biobanks and AI-driven cardiovascular risk assessment represents the international, collaborative future of the field. Her leadership will help ASHG maintain its status as a truly global entity.
Chronology: From Discovery to Implementation
The evolution of ASHG leadership reflects the broader trajectory of the genetics field over the last three decades:
- 1948–1990s: The Foundational Era. ASHG primarily served as a hub for discovery, mapping the basic principles of human heredity.
- 2000s–2010s: The Genomic Revolution. With the completion of the Human Genome Project, the focus shifted toward large-scale sequencing, genome-wide association studies (GWAS), and the professionalization of genetic counseling.
- 2020–2025: The Translational Pivot. The Society prioritized the "bench-to-bedside" approach, ensuring that genomic tools were not just academic interests but clinical necessities.
- 2026 and Beyond: The Integration Age. The 2027 leadership class represents a deliberate shift toward embedding genetics into the broader healthcare infrastructure, leveraging AI to manage massive datasets, and ensuring these advancements reach diverse, underserved, and global populations.
Supporting Data: The Growing Need for Genomic Leadership
The selection of these leaders comes against a backdrop of explosive growth in the genomic sector. According to recent industry reports, the global genomics market is projected to reach unprecedented valuations by 2030, driven largely by the falling cost of sequencing and the rising demand for precision oncology and rare disease diagnostics.
However, challenges persist. Data from the 2026 ASHG strategic review highlights three primary areas of concern:
- Workforce Shortages: The demand for clinical geneticists and certified genetic counselors is currently outstripping the supply, particularly in non-metropolitan areas.
- Bioethical Hurdles: As AI becomes more prevalent in diagnostic algorithms, the Society must provide robust ethical frameworks to prevent algorithmic bias.
- Data Disparity: Historically, genomic databases have been heavily skewed toward populations of European descent. Dr. Starlard-Davenport and the incoming board are tasked with correcting this "diversity deficit" to ensure treatments are effective for all humans, regardless of ancestry.
Official Responses and Strategic Implications
"The election of this cohort is not just a procedural milestone; it is a mandate for change," noted a spokesperson for the ASHG. "By electing a board that blends clinical practice, computational biology, and community health advocacy, the membership is signaling that they want the Society to be more than a scientific publisher—they want it to be an engine for systemic health reform."
Implications for the Healthcare System
The incoming leadership is expected to prioritize:
- AI Policy Frameworks: With Dr. Marderstein and Dr. Campbell’s combined expertise, the Society is expected to release a series of white papers in 2027 outlining how clinical institutions can safely integrate AI into electronic health records (EHRs) for genomic risk stratification.
- Advocacy for Reimbursement: A major barrier to genomic medicine remains the insurance reimbursement landscape. The Board will likely ramp up its government and public advocacy efforts to ensure that genetic testing—particularly for rare diseases—is classified as a standard of care rather than an elective luxury.
- Global Standardization: Through the work of international fellows like Dr. Wolford, ASHG aims to harmonize data-sharing standards, allowing for larger, more diverse datasets that can accelerate drug discovery globally.
Conclusion: A New Chapter for ASHG
As the American Society of Human Genetics looks toward 2027, the message is clear: the era of genomic discovery is transitioning into the era of genomic responsibility. Under the guidance of Dr. Wendy Chung and the new Board of Directors, the Society is poised to navigate the complexities of AI, the imperative of health equity, and the challenges of clinical integration.
For the nearly 8,000 members of ASHG—and the millions of patients who rely on the innovations emerging from their laboratories—the next three years represent a critical window. The leaders elected this week are tasked with ensuring that the genomic revolution delivers on its original promise: a more precise, more equitable, and more effective future for human health.
The term for the new Board of Directors and the President-Elect will officially begin on January 1, 2027. As the society prepares for this transition, the scientific community awaits the first policy initiatives from this new leadership team, which are expected to be unveiled during the 2027 Annual Meeting.
For more information regarding the American Society of Human Genetics or to view the full list of leadership, please visit www.ashg.org.
About the Author
